改善2型心肌梗死患者的风险分层
该研究基于前瞻性多中心队列推导并验证了T2-risk评分,用于预测2型心肌梗死患者1年内死亡或心肌梗死。T2-risk评分纳入年龄、缺血性心脏病、心力衰竭、糖尿病、心电图心肌缺血、心率、贫血、eGFR和最大肌钙蛋白浓度,在推导队列中AUC为0.76(95%CI 0.73-0.79),并在单中心和多中心验证队列中表现良好。
要点
- T2-risk评分可预测2型心肌梗死患者1年内死亡或心肌梗死。
- 评分在推导队列中AUC为0.76(95%CI 0.73-0.79)。
- 在所有队列中,T2-risk评分区分度优于GRACE 2.0风险评分。
核心结论
- T2-risk评分在不同医疗环境中表现良好,可帮助临床医生进行预后判断并更有效地指导检查和预防性治疗。
研究设计与样本
- T2-risk评分在前瞻性多中心连续2型心肌梗死患者队列中推导,使用Cox比例风险模型预测1年心肌梗死或死亡。
- 推导队列1121例,单中心验证队列250例,多中心验证队列253例。
主要发现
- 推导队列、单中心验证队列和多中心验证队列的主要结局发生率分别为27%(297/1121)、26%(66/250)和14%(35/253)。
- T2-risk评分在推导队列中AUC为0.76(95%CI 0.73-0.79),校准良好。
- 单中心验证队列AUC为0.83(95%CI 0.77-0.88),多中心验证队列AUC为0.74(95%CI 0.64-0.83)。
- T2-risk评分在所有队列中区分度均优于GRACE 2.0风险评分。
关键数值与推荐
- T2-risk评分纳入年龄、缺血性心脏病、心力衰竭、糖尿病、心电图心肌缺血、心率、贫血、eGFR和最大肌钙蛋白浓度。
临床怎么用
- T2-risk评分可用于2型心肌梗死患者的预后判断,并指导检查和预防性治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite poor cardiovascular outcomes, there are no dedicated, validated risk stratification tools to guide investigation or treatment in type 2 myocardial infarction. OBJECTIVES: The goal of this study was to derive and validate a risk stratification tool for the prediction of death or future myocardial infarction in patients with type 2 myocardial infarction. METHODS: The T2-risk score was developed in a prospective multicenter cohort of consecutive patients with type 2 myocardial infarction. Cox proportional hazards models were constructed for the primary outcome of myocardial infarction or death at 1 year using variables selected a priori based on clinical importance. Discrimination was assessed by area under the receiving-operating characteristic curve (AUC). Calibration was investigated graphically. The tool was validated in a single-center cohort of consecutive patients and in a multicenter cohort study from sites across Europe. RESULTS: There were 1,121, 250, and 253 patients in the derivation, single-center, and multicenter validation cohorts, with the primary outcome occurring in 27% (297 of 1,121), 26% (66 of 250), and 14% (35 of 253) of patients, respectively. The T2-risk score incorporating age, ischemic heart disease, heart failure, diabetes mellitus, myocardial ischemia on electrocardiogram, heart rate, anemia, estimated glomerular filtration rate, and maximal cardiac troponin concentration had good discrimination (AUC: 0.76; 95% CI: 0.73-0.79) for the primary outcome and was well calibrated. Discrimination was similar in the consecutive patient (AUC: 0.83; 95% CI: 0.77-0.88) and multicenter (AUC: 0.74; 95% CI: 0.64-0.83) cohorts. T2-risk provided improved discrimination over the Global Registry of Acute Coronary Events 2.0 risk score in all cohorts. CONCLUSIONS: The T2-risk score performed well in different health care settings and could help clinicians to prognosticate, as well as target investigation and preventative therapies more effectively. (High-Sensitivity Troponin in the Evaluation of Patients With Suspected Acute Coronary Syndrome [High-STEACS]; NCT01852123).
引用
- Taggart, Monterrubio-Gómez, Roos, et al. Improving Risk Stratification for Patients With Type 2 Myocardial Infarction. J Am Coll Cardiol. 2023. PMID: 36631210. doi:10.1016/j.jacc.2022.10.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。